These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 15134159

  • 1. Considerations in the choice of oral vs. transdermal hormone therapy: a review.
    Minkin MJ.
    J Reprod Med; 2004 Apr; 49(4):311-20. PubMed ID: 15134159
    [Abstract] [Full Text] [Related]

  • 2. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.
    Modena MG, Sismondi P, Mueck AO, Kuttenn F, Lignières Bd, Verhaeghe J, Foidart JM, Caufriez A, Genazzani AR, TREAT.
    Maturitas; 2005 Sep 16; 52(1):1-10. PubMed ID: 15963666
    [Abstract] [Full Text] [Related]

  • 3. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results.
    Kuhl H, Stevenson J.
    Gynecol Endocrinol; 2006 Jun 16; 22(6):303-17. PubMed ID: 16785155
    [Abstract] [Full Text] [Related]

  • 4. Quality of life assessment in a chemoprevention trial: fenretinide and oral or transdermal HRT.
    Serrano D, Mariani L, Mora S, Guerrieri-Gonzaga A, Cazzaniga M, Daldoss C, Ramazzotto F, Feroce I, Decensi A, Bonanni B.
    Maturitas; 2006 Aug 20; 55(1):69-75. PubMed ID: 16500052
    [Abstract] [Full Text] [Related]

  • 5. Hormone therapy and the cardiovascular system: the critical role of progestins.
    Sitruk-Ware RL.
    Climacteric; 2003 Oct 20; 6 Suppl 3():21-8. PubMed ID: 15018245
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [After the early termination of the Women's Health Initiative study. New American recommendations for postmenopausal hormone therapy].
    Stjernquist M, North American Menopause Society (NAMS) Advisory Panel.
    Lakartidningen; 2003 May 15; 100(20):1790-7. PubMed ID: 12806859
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.
    Prescrire Int; 2004 Jun 15; 13(71):106-9. PubMed ID: 15233153
    [Abstract] [Full Text] [Related]

  • 14. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
    Keramaris NC, Christodoulakos GE, Lambrinoudaki IV, Dalamanga A, Alexandrou AP, Bramis J, Bastounis E, Creatsas GC.
    Climacteric; 2007 Oct 15; 10(5):400-7. PubMed ID: 17852143
    [Abstract] [Full Text] [Related]

  • 15. Serum estrogen level after hormone replacement therapy and body mass index in postmenopausal and bilaterally ovariectomized women.
    Yasui T, Uemura H, Umino Y, Takikawa M, Saito S, Kuwahara A, Matsuzaki T, Maegawa M, Furumoto H, Miura M, Irahara M.
    Maturitas; 2005 Jan 10; 50(1):19-29. PubMed ID: 15590210
    [Abstract] [Full Text] [Related]

  • 16. High C-reactive protein levels are associated with oral hormonal menopausal therapy but not with intrauterine levonorgestrel and transdermal estradiol.
    Blumenfeld Z, Boulman N, Leiba R, Siegler E, Shachar S, Linn R, Levy Y.
    Scand J Clin Lab Invest; 2007 Jan 10; 67(3):257-63. PubMed ID: 17454839
    [Abstract] [Full Text] [Related]

  • 17. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys.
    Wood CE, Register TC, Lees CJ, Chen H, Kimrey S, Cline JM.
    Breast Cancer Res Treat; 2007 Jan 10; 101(2):125-34. PubMed ID: 16841178
    [Abstract] [Full Text] [Related]

  • 18. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study.
    Bots ML, Evans GW, Riley W, McBride KH, Paskett ED, Helmond FA, Grobbee DE, OPAL Investigators.
    Eur Heart J; 2006 Mar 10; 27(6):746-55. PubMed ID: 16415304
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.